Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor

Journal of Biological Chemistry

Volumn 287, Issue 44, 2012, Pages 37066-37077

  Gregory, Karen J ^a   Sexton, Patrick M ^a   Tobin, Andrew B ^b   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION STATE; ACTIVE STATE; ALLOSTERIC SITE; AROMATIC RESIDUES; CONFORMATIONAL CONSTRAINTS; G PROTEIN COUPLED RECEPTORS; MUTATIONAL ANALYSIS; STRUCTURE-FUNCTION RELATIONSHIP;

BIOCHEMISTRY;

BIOLOGY;

AROMATIC COMPOUND; G PROTEIN COUPLED RECEPTOR; MUSCARINIC M2 RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ALLOSTERIC SITE; AMINO ACID SUBSTITUTION; ANIMALS; CARBACHOL; CHO CELLS; CRICETINAE; HALF-LIFE; HUMANS; KINETICS; MODELS, MOLECULAR; MUSCARINIC AGONISTS; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PILOCARPINE; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTOR, MUSCARINIC M2; SIGNAL TRANSDUCTION;

EID: 84868223603     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.408534     Document Type: Article

References (37)

1. M. C., and , H. B. (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357
2. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996
3. Lefkowitz, R. J. (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25, 413-422
4. Shenoy, S. K., and Lefkowitz, R. J. (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32, 521-533
5. Kenakin, T. (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4, 919-927
6. Violin, J. D., and Lefkowitz, R. J. (2007)β-Arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol. Sci. 28, 416-422
7. Reiter, E., Ahn, S., Shukla, A. K., and Lefkowitz, R. J. (2012) Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179-197
8. Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., and Lefkowitz, R. J. (2007) A unique mechanism of betablocker action: carvedilol stimulatesβ-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 16657-16662
9. Gesty-Palmer, D., and Luttrell, L. M. (2011) "Biasing" the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br. J. Pharmacol. 164, 59-67
10. Gesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C. D., Wang, S., Eckhardt, A. E., Cowan, C. L., Spurney, R. F., Luttrell, L. M., and Lefkowitz, R. J. (2006) Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281, 10856-10864
11. Violin, J. D., DeWire, S. M., Yamashita, D., Rominger, D. H., Nguyen, L., Schiller, K., Whalen, E. J., Gowen, M., and Lark, M. W. (2010) Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335, 572-579
12. Barker, E. L., Westphal, R. S., Schmidt, D., and Sanders-Bush, E. (1994) Constitutively active 5-hydroxytryptamine 2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 269, 11687-11690
13. Blanpain, C., Vanderwinden, J. M., Cihak, J., Wittamer, V., Le Poul, E., Issafras, H., Stangassinger, M., Vassart, G., Marullo, S., Schlndorff, D., Parmentier, M., and Mack, M. (2002) Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell 13, 723-737
14. Labrecque, J., Fargin, A., Bouvier, M., Chidiac, P., and Dennis, M. (1995) Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol. Pharmacol. 48, 150-159
15. Roettger, B. F., Ghanekar, D., Rao, R., Toledo, C., Yingling, J., Pinon, D., and Miller, L. J. (1997) Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 51, 357-362
16. Wei, H., Ahn, S., Shenoy, S. K., Karnik, S. S., Hunyady, L., Luttrell, L. M., and Lefkowitz, R. J. (2003) Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 100, 10782-10787
17. Whistler, J. L., and von Zastrow, M. (1998) Morphine-activated opioid receptors elude desensitization by β-arrestin. Proc. Natl. Acad. Sci. U.S.A. 95, 9914-9919
18. Kenakin, T., and Miller, L. J. (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304
19. Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M., and Christopoulos, A. (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol. Chem. 285, 7459-7474
20. Evans, B. A., Broxton, N., Merlin, J., Sato, M., Hutchinson, D. S., Christopoulos, A., and Summers, R. J. (2011) Quantification of functional selectivity at the human (1A)-adrenoceptor. Mol. Pharmacol. 79, 298-307
21. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., and Novick, S. (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193-203
22. Koole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., and Sexton, P. M. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol. Pharmacol. 78, 456-465
23. Avlani, V. A., Gregory, K. J., Morton, C. J., Parker, M. W., Sexton, P. M., and Christopoulos, A. (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J. Biol. Chem. 282, 25677-25686
24. May, L. T., Avlani, V. A., Langmead, C. J., Herdon, H. J., Wood, M. D., Sexton, P. M., and Christopoulos, A. (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 72, 463-476
25. Avlani, V., May, L. T., Sexton, P. M., and Christopoulos, A. (2004) Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308, 1062-1072
26. Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., and Christopoulos, A. (2008) A novel mechanism of G proteincoupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312-29321
27. Black, J. W., and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141-162
28. Christopoulos, A. (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol. Sci. 19, 351-357
29. Avlani, V. A., Langmead, C. J., Guida, E., Wood, M. D., Tehan, B. G., Herdon, H. J., Watson, J. M., Sexton, P. M., and Christopoulos, A. (2010) Orthosteric and allosteric modes of interaction of novel selective agonists of theM1muscarinic acetylcholine receptor. Mol. Pharmacol. 78, 94-104
30. Lebon, G., Langmead, C. J., Tehan, B. G., and Hulme, E. C. (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 75, 331-341
31. Matsui, H., Lazareno, S., and Birdsall, N. J. (1995) Probing of the location of the allosteric site onm1muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47, 88-98
32. Spalding, T. A., Ma, J. N., Ott, T. R., Friberg, M., Bajpai, A., Bradley, S. R., Davis, R. E., Brann, M. R., and Burstein, E. S. (2006) Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and Ndesmethylclozapine: evidence for three distinct modes of receptor activation. Mol. Pharmacol. 70, 1974-1983
33. Spalding, T. A., Trotter, C., Skjaerbaek, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., and Brann, M. R. (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 61, 1297-1302
34. Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., and Conn, P. J. (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. U.S.A. 100, 13674-13679
35. Rosethorne, E. M., and Charlton, S. J. (2011) Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. Mol. Pharmacol. 79, 749-757
36. Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., Dewire, S. M., Violin, J. D., and Lefkowitz, R. J. (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377
37. Reiter, E., and Lefkowitz, R. J. (2006) GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17, 159-165